Open AccessCYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials
Author(s) -
Qi Cao,
Peng Bai,
Deyao Shi,
Jiali Liao,
Hangchuan Shi,
Yifei Xing,
Ke Chen,
Xiaoping Zhang
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_295_18
Subject(s) - medicine , prostate cancer , hazard ratio , abiraterone acetate , placebo , oncology , meta analysis , cochrane library , randomized controlled trial , confidence interval , cancer , androgen deprivation therapy , pathology , alternative medicine
CYP17 inhibitors can block androgen production both intratumorally and systemically, thus attenuating the progression of prostate cancer (PCa). Many randomized controlled trials (RCTs) showed promising results that men with metastatic castration-resistant PCa (mCRPC) might benefit from treatment with CYP17 inhibitors such as abiraterone acetate and orteronel. The goal of this study was to evaluate the efficacy of CYP17 inhibitors for the prognosis in patients with mCRPC.